$KALA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kala Pharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Kala Pharmaceuticals, Inc.. Get notifications about new insider transactions in Kala Pharmaceuticals, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 21 2021 | KALA | Kala Pharmaceutica ... | Shah Rajeev M. | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K | |
| Jun 21 2021 | KALA | Kala Pharmaceutica ... | PERRY GREGORY D | Grant | A | 0.00 | 20,000 | 0 | 40,000 | 20 K to 40 K (+100.00 %) | |
| Jun 21 2021 | KALA | Kala Pharmaceutica ... | Grunberg Gregory | Grant | A | 0.00 | 20,000 | 0 | 40,000 | 20 K to 40 K (+100.00 %) | |
| Mar 03 2021 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Option Exercise | M | 2.30 | 9,500 | 21,850 | 53,736 | |
| Mar 03 2021 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Buy | M | 2.30 | 9,500 | 21,850 | 243,015 | 233.5 K to 243 K (+4.07 %) |
| Feb 26 2021 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Option Exercise | M | 2.30 | 47,000 | 108,100 | 63,236 | |
| Feb 26 2021 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Buy | M | 2.30 | 47,000 | 108,100 | 233,515 | 186.5 K to 233.5 K (+25.20 %) |
| Jan 05 2021 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Option Exercise | A | 6.86 | 90,667 | 621,976 | 90,667 | |
| Jan 05 2021 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Grant | A | 0.00 | 22,666 | 0 | 186,515 | 163.8 K to 186.5 K (+13.83 %) |
| Jan 05 2021 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Option Exercise | A | 6.86 | 110,000 | 754,600 | 110,000 | |
| Jan 05 2021 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Option Exercise | A | 6.86 | 110,000 | 754,600 | 110,000 | |
| Jan 05 2021 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Grant | A | 0.00 | 27,500 | 0 | 137,500 | 110 K to 137.5 K (+25.00 %) |
| Jan 05 2021 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Grant | A | 0.00 | 27,500 | 0 | 137,500 | 110 K to 137.5 K (+25.00 %) |
| Jan 05 2021 | KALA | Kala Pharmaceutica ... | Reumuth Mary | Chief Financial Off ... | Option Exercise | A | 6.86 | 90,667 | 621,976 | 90,667 | |
| Jan 05 2021 | KALA | Kala Pharmaceutica ... | Reumuth Mary | Chief Financial Off ... | Grant | A | 0.00 | 22,666 | 0 | 147,959 | 125.3 K to 148 K (+18.09 %) |
| Jan 05 2021 | KALA | Kala Pharmaceutica ... | Reumuth Mary | Chief Financial Off ... | Option Exercise | A | 6.86 | 90,667 | 621,976 | 90,667 | |
| Jan 05 2021 | KALA | Kala Pharmaceutica ... | Reumuth Mary | Chief Financial Off ... | Grant | A | 0.00 | 22,666 | 0 | 147,959 | 125.3 K to 148 K (+18.09 %) |
| Oct 28 2020 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Buy | P | 7.60 | 40 | 304 | 42 | 2 to 42 (+2,000.00 %) |
| Oct 28 2020 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Buy | P | 13.39 | 2 | 27 | 2 | 0 to 2 |
| Oct 28 2020 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Grant | A | 0.00 | 81,000 | 0 | 110,000 | 29 K to 110 K (+279.31 %) |
| Oct 28 2020 | KALA | Kala Pharmaceutica ... | Trachtenberg Eric | See Remarks | Grant | A | 0.00 | 61,000 | 0 | 105,901 | 44.9 K to 105.9 K (+135.85 %) |
| Oct 28 2020 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Buy | P | 7.60 | 40 | 304 | 42 | 2 to 42 (+2,000.00 %) |
| Oct 28 2020 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Buy | P | 13.39 | 2 | 27 | 2 | 0 to 2 |
| Oct 28 2020 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Grant | A | 0.00 | 81,000 | 0 | 110,000 | 29 K to 110 K (+279.31 %) |
| Oct 28 2020 | KALA | Kala Pharmaceutica ... | Trachtenberg Eric | See Remarks | Grant | A | 0.00 | 61,000 | 0 | 105,901 | 44.9 K to 105.9 K (+135.85 %) |
| Oct 28 2020 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Grant | A | 0.00 | 61,000 | 0 | 163,849 | 102.8 K to 163.8 K (+59.31 %) |
| Oct 28 2020 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Grant | A | 0.00 | 81,000 | 0 | 276,496 | 195.5 K to 276.5 K (+41.43 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Reumuth Mary | Chief Financial Off ... | Grant | A | 0.00 | 16,000 | 0 | 64,293 | 48.3 K to 64.3 K (+33.13 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Shah Rajeev M. | Director | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Rosen Howard B | Director | Grant | A | 0.00 | 20,000 | 0 | 24,824 | 4.8 K to 24.8 K (+414.59 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Iwicki Mark T | Chief Executive Off ... | Grant | A | 0.00 | 49,560 | 0 | 49,560 | 0 to 49.6 K |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Paull Robert Bradley | Director | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Trachtenberg Eric | See Remarks | Grant | A | 0.00 | 16,000 | 0 | 44,901 | 28.9 K to 44.9 K (+55.36 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Rosen Howard B | Director | Option Exercise | M | 0.47 | 1,944 | 914 | 0 | |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Rosen Howard B | Director | Option Exercise | M | 0.68 | 2,880 | 1,958 | 0 | |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Rosen Howard B | Director | Buy | M | 0.47 | 1,944 | 914 | 4,824 | 2.9 K to 4.8 K (+67.50 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Rosen Howard B | Director | Buy | M | 0.68 | 2,880 | 1,958 | 2,880 | 0 to 2.9 K |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Paull Robert Bradley | Director | Buy | J | 0.00 | 1,287 | 0 | 2,361 | 1.1 K to 2.4 K (+119.83 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Paull Robert Bradley | Director | Buy | J | 0.00 | 477 | 0 | 1,074 | 597 to 1.1 K (+79.90 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Paull Robert Bradley | Director | Buy | J | 0.00 | 597 | 0 | 597 | 0 to 597 |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Grunberg Gregory | Director | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Grant | A | 0.00 | 19,000 | 0 | 195,496 | 176.5 K to 195.5 K (+10.77 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | KOVEN ANDREW I | Director | Grant | A | 0.00 | 28,000 | 0 | 28,000 | 0 to 28 K |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Grant | A | 0.00 | 16,000 | 0 | 102,849 | 86.8 K to 102.8 K (+18.42 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Grant | A | 0.00 | 19,000 | 0 | 29,000 | 10 K to 29 K (+190.00 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Trachtenberg Eric | See Remarks | Grant | A | 0.00 | 16,000 | 0 | 44,901 | 28.9 K to 44.9 K (+55.36 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Rosen Howard B | Director | Option Exercise | M | 0.47 | 1,944 | 914 | 0 | |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Rosen Howard B | Director | Option Exercise | M | 0.68 | 2,880 | 1,958 | 0 | |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Rosen Howard B | Director | Buy | M | 0.47 | 1,944 | 914 | 4,824 | 2.9 K to 4.8 K (+67.50 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Rosen Howard B | Director | Buy | M | 0.68 | 2,880 | 1,958 | 2,880 | 0 to 2.9 K |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Paull Robert Bradley | Director | Buy | J | 0.00 | 1,287 | 0 | 2,361 | 1.1 K to 2.4 K (+119.83 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Paull Robert Bradley | Director | Buy | J | 0.00 | 477 | 0 | 1,074 | 597 to 1.1 K (+79.90 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Paull Robert Bradley | Director | Buy | J | 0.00 | 597 | 0 | 597 | 0 to 597 |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Grunberg Gregory | Director | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Grant | A | 0.00 | 19,000 | 0 | 195,496 | 176.5 K to 195.5 K (+10.77 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | KOVEN ANDREW I | Director | Grant | A | 0.00 | 28,000 | 0 | 28,000 | 0 to 28 K |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Grant | A | 0.00 | 16,000 | 0 | 102,849 | 86.8 K to 102.8 K (+18.42 %) |
| Jun 29 2020 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Grant | A | 0.00 | 19,000 | 0 | 29,000 | 10 K to 29 K (+190.00 %) |
| Jun 22 2020 | KALA | Kala Pharmaceutica ... | Trachtenberg Eric | See Remarks | Option Exercise | M | 5.19 | 28,901 | 149,996 | 136,099 | |
| Jun 22 2020 | KALA | Kala Pharmaceutica ... | Trachtenberg Eric | See Remarks | Buy | M | 5.19 | 28,901 | 149,996 | 28,901 | 0 to 28.9 K |
| Jun 11 2020 | KALA | Kala Pharmaceutica ... | Reumuth Mary | Chief Financial Off ... | Option Exercise | M | 2.30 | 11,520 | 26,496 | 0 | |
| Jun 11 2020 | KALA | Kala Pharmaceutica ... | Reumuth Mary | Chief Financial Off ... | Option Exercise | M | 2.30 | 15,360 | 35,328 | 0 | |
| Jun 11 2020 | KALA | Kala Pharmaceutica ... | Reumuth Mary | Chief Financial Off ... | Option Exercise | M | 5.21 | 5,077 | 26,451 | 0 | |
| Jun 11 2020 | KALA | Kala Pharmaceutica ... | Reumuth Mary | Chief Financial Off ... | Option Exercise | M | 2.30 | 11,520 | 26,496 | 0 | |
| Jun 11 2020 | KALA | Kala Pharmaceutica ... | Reumuth Mary | Chief Financial Off ... | Buy | M | 2.30 | 11,520 | 26,496 | 48,293 | 36.8 K to 48.3 K (+31.33 %) |
| Jun 11 2020 | KALA | Kala Pharmaceutica ... | Reumuth Mary | Chief Financial Off ... | Buy | M | 2.30 | 15,360 | 35,328 | 36,773 | 21.4 K to 36.8 K (+71.73 %) |
| Jun 11 2020 | KALA | Kala Pharmaceutica ... | Reumuth Mary | Chief Financial Off ... | Buy | M | 5.21 | 5,077 | 26,451 | 21,413 | 16.3 K to 21.4 K (+31.08 %) |
| Jun 11 2020 | KALA | Kala Pharmaceutica ... | Reumuth Mary | Chief Financial Off ... | Buy | M | 2.30 | 11,520 | 26,496 | 16,336 | 4.8 K to 16.3 K (+239.20 %) |
| Apr 13 2020 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Option Exercise | M | 3.34 | 47,644 | 159,131 | 13,508 | |
| Apr 13 2020 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Option Exercise | M | 2.30 | 18,247 | 41,968 | 0 | |
| Apr 13 2020 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Option Exercise | M | 0.68 | 1,880 | 1,278 | 0 | |
| Apr 13 2020 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Buy | M | 3.34 | 47,644 | 159,131 | 176,496 | 128.9 K to 176.5 K (+36.98 %) |
| Apr 13 2020 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Buy | M | 2.30 | 18,247 | 41,968 | 128,852 | 110.6 K to 128.9 K (+16.50 %) |
| Apr 13 2020 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Buy | M | 0.68 | 1,880 | 1,278 | 110,605 | 108.7 K to 110.6 K (+1.73 %) |
| Apr 01 2020 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Option Exercise | M | 2.30 | 31,000 | 71,300 | 75,236 | |
| Apr 01 2020 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Buy | M | 2.30 | 31,000 | 71,300 | 86,849 | 55.8 K to 86.8 K (+55.51 %) |
| Mar 17 2020 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Buy | P | 5.75 | 10,000 | 57,500 | 10,000 | 0 to 10 K |
| Mar 17 2020 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Buy | P | 5.75 | 10,000 | 57,500 | 10,000 | 0 to 10 K |
| Mar 16 2020 | KALA | Kala Pharmaceutica ... | Grunberg Gregory | Director | Buy | P | 7.89 | 2,534,854 | 19,999,998 | 2,534,854 | 0 to 2.5 M |
| Mar 13 2020 | KALA | Kala Pharmaceutica ... | Shah Rajeev M. | Director | Buy | P | 7.89 | 6,337,135 | 49,999,995 | 10,874,613 | 4.5 M to 10.9 M (+139.66 %) |
| Mar 13 2020 | KALA | Kala Pharmaceutica ... | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | P | 7.89 | 6,337,135 | 49,999,995 | 10,874,613 | 4.5 M to 10.9 M (+139.66 %) |
| Jan 03 2020 | KALA | Kala Pharmaceutica ... | Iwicki Mark T | Chief Executive Off ... | Option Exercise | A | 3.84 | 365,000 | 1,401,600 | 365,000 | |
| Jan 03 2020 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Option Exercise | A | 3.84 | 120,000 | 460,800 | 120,000 | |
| Jan 03 2020 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Option Exercise | A | 3.84 | 120,000 | 460,800 | 120,000 | |
| Jan 03 2020 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Option Exercise | A | 3.84 | 120,000 | 460,800 | 120,000 | |
| Oct 15 2019 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Option Exercise | A | 3.45 | 175,000 | 603,750 | 175,000 | |
| Oct 15 2019 | KALA | Kala Pharmaceutica ... | Trachtenberg Eric | See Remarks | Option Exercise | A | 3.45 | 100,000 | 345,000 | 100,000 | |
| Jun 07 2019 | KALA | Kala Pharmaceutica ... | Rosen Howard B | Director | Option Exercise | A | 5.35 | 21,000 | 112,350 | 21,000 | |
| Jun 07 2019 | KALA | Kala Pharmaceutica ... | PERRY GREGORY D | Director | Option Exercise | A | 5.35 | 21,000 | 112,350 | 21,000 | |
| Jun 07 2019 | KALA | Kala Pharmaceutica ... | Paull Robert Bradley | Director | Option Exercise | A | 5.35 | 21,000 | 112,350 | 21,000 | |
| Jun 07 2019 | KALA | Kala Pharmaceutica ... | Grunberg Gregory | Director | Option Exercise | A | 5.35 | 21,000 | 112,350 | 21,000 | |
| Jun 07 2019 | KALA | Kala Pharmaceutica ... | KOVEN ANDREW I | Director | Option Exercise | A | 5.35 | 21,000 | 112,350 | 21,000 | |
| Jun 07 2019 | KALA | Kala Pharmaceutica ... | Shah Rajeev M. | Director | Option Exercise | A | 5.35 | 21,000 | 112,350 | 21,000 | |
| Jun 03 2019 | KALA | Kala Pharmaceutica ... | Rosen Howard B | Director | Buy | P | 5.42 | 5,000 | 27,100 | 8,240 | 3.2 K to 8.2 K (+154.32 %) |
| Jan 04 2019 | KALA | Kala Pharmaceutica ... | Iwicki Mark T | Chief Executive Off ... | Option Exercise | A | 5.19 | 460,000 | 2,387,400 | 460,000 | |
| Jan 04 2019 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Option Exercise | A | 5.19 | 175,000 | 908,250 | 175,000 | |
| Jan 04 2019 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Option Exercise | A | 5.19 | 150,000 | 778,500 | 150,000 | |
| Jan 04 2019 | KALA | Kala Pharmaceutica ... | Trachtenberg Eric | See Remarks | Option Exercise | A | 5.19 | 165,000 | 856,350 | 165,000 | |
| Jan 04 2019 | KALA | Kala Pharmaceutica ... | Reumuth Mary | Chief Financial Off ... | Option Exercise | A | 5.19 | 150,000 | 778,500 | 150,000 | |
| Oct 09 2018 | KALA | Kala Pharmaceutica ... | Grunberg Gregory | Director | Buy | P | 8.25 | 606,060 | 4,999,995 | 2,877,006 | 2.3 M to 2.9 M (+26.69 %) |
| Oct 05 2018 | KALA | Kala Pharmaceutica ... | Shah Rajeev M. | Director | Buy | P | 8.25 | 2,424,242 | 19,999,997 | 4,537,478 | 2.1 M to 4.5 M (+114.72 %) |
| Oct 05 2018 | KALA | Kala Pharmaceutica ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 8.25 | 2,424,242 | 19,999,997 | 4,537,478 | 2.1 M to 4.5 M (+114.72 %) |
| Oct 05 2018 | KALA | Kala Pharmaceutica ... | Shah Rajeev M. | Director | Buy | P | 8.25 | 2,424,242 | 19,999,997 | 4,537,478 | 2.1 M to 4.5 M (+114.72 %) |
| Oct 05 2018 | KALA | Kala Pharmaceutica ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 8.25 | 2,424,242 | 19,999,997 | 4,537,478 | 2.1 M to 4.5 M (+114.72 %) |
| Jun 15 2018 | KALA | Kala Pharmaceutica ... | Shah Rajeev M. | Director | Option Exercise | A | 13.73 | 12,960 | 177,941 | 12,960 | |
| Jun 15 2018 | KALA | Kala Pharmaceutica ... | LANGER ROBERT | Director | Option Exercise | A | 13.73 | 12,960 | 177,941 | 12,960 | |
| Jun 14 2018 | KALA | Kala Pharmaceutica ... | KOVEN ANDREW I | Director | Option Exercise | A | 13.73 | 12,960 | 177,941 | 12,960 | |
| Jun 14 2018 | KALA | Kala Pharmaceutica ... | Grunberg Gregory | Director | Option Exercise | A | 13.73 | 12,960 | 177,941 | 12,960 | |
| Jun 14 2018 | KALA | Kala Pharmaceutica ... | Hill Paulina | Director | Option Exercise | A | 13.73 | 12,960 | 177,941 | 12,960 | |
| Jun 14 2018 | KALA | Kala Pharmaceutica ... | Paull Robert Bradley | Director | Option Exercise | A | 13.73 | 12,960 | 177,941 | 12,960 | |
| Jun 14 2018 | KALA | Kala Pharmaceutica ... | Rosen Howard B | Director | Option Exercise | A | 13.73 | 12,960 | 177,941 | 12,960 | |
| Apr 09 2018 | KALA | Kala Pharmaceutica ... | Trachtenberg Eric | General Counsel and ... | Option Exercise | A | 16.62 | 150,000 | 2,493,000 | 150,000 | |
| Mar 02 2018 | KALA | Kala Pharmaceutica ... | PERRY GREGORY D | Director | Option Exercise | A | 14.05 | 25,920 | 364,176 | 25,920 | |
| Mar 02 2018 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Option Exercise | M | 2.24 | 5,769 | 12,923 | 0 | |
| Mar 02 2018 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Option Exercise | M | 2.30 | 4,000 | 9,200 | 106,236 | |
| Mar 02 2018 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Buy | M | 2.24 | 5,769 | 12,923 | 55,849 | 50.1 K to 55.8 K (+11.52 %) |
| Mar 02 2018 | KALA | Kala Pharmaceutica ... | Chen Hongming | Chief Scientific Of ... | Buy | M | 2.30 | 4,000 | 9,200 | 50,080 | 46.1 K to 50.1 K (+8.68 %) |
| Feb 09 2018 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Option Exercise | A | 12.86 | 25,000 | 321,500 | 25,000 | |
| Feb 09 2018 | KALA | Kala Pharmaceutica ... | Iwicki Mark T | Chief Executive Off ... | Option Exercise | A | 12.86 | 230,000 | 2,957,800 | 230,000 | |
| Feb 09 2018 | KALA | Kala Pharmaceutica ... | Reumuth Mary | Chief Financial Off ... | Option Exercise | A | 12.86 | 70,000 | 900,200 | 70,000 | |
| Feb 09 2018 | KALA | Kala Pharmaceutica ... | LaRussa Michele | Sr. VP, Regulatory ... | Option Exercise | A | 12.86 | 8,000 | 102,880 | 8,000 | |
| Feb 06 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.73 | 37,840 | 557,383 | 3,422,840 | 3.4 M to 3.4 M (+1.12 %) |
| Feb 02 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.99 | 22,840 | 342,372 | 3,385,000 | 3.4 M to 3.4 M (+0.68 %) |
| Feb 02 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 15.00 | 339,400 | 5,091,000 | 3,362,160 | 3 M to 3.4 M (+11.23 %) |
| Jan 30 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.99 | 50,000 | 749,500 | 3,022,760 | 3 M to 3 M (+1.68 %) |
| Jan 30 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.93 | 22,760 | 339,807 | 2,972,760 | 3 M to 3 M (+0.77 %) |
| Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.91 | 64,637 | 963,738 | 2,950,000 | 2.9 M to 3 M (+2.24 %) |
| Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.99 | 4,363 | 65,401 | 2,885,363 | 2.9 M to 2.9 M (+0.15 %) |
| Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.98 | 75,000 | 1,123,500 | 2,881,000 | 2.8 M to 2.9 M (+2.67 %) |
| Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.95 | 74,931 | 1,120,218 | 2,806,000 | 2.7 M to 2.8 M (+2.74 %) |
| Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.50 | 38,354 | 556,133 | 2,731,069 | 2.7 M to 2.7 M (+1.42 %) |
| Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.91 | 64,637 | 963,738 | 2,950,000 | 2.9 M to 3 M (+2.24 %) |
| Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.99 | 4,363 | 65,401 | 2,885,363 | 2.9 M to 2.9 M (+0.15 %) |
| Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.98 | 75,000 | 1,123,500 | 2,881,000 | 2.8 M to 2.9 M (+2.67 %) |
| Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.95 | 74,931 | 1,120,218 | 2,806,000 | 2.7 M to 2.8 M (+2.74 %) |
| Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.50 | 38,354 | 556,133 | 2,731,069 | 2.7 M to 2.7 M (+1.42 %) |
| Jan 12 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 15.40 | 28,446 | 438,068 | 2,692,715 | 2.7 M to 2.7 M (+1.07 %) |
| Jan 12 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 13.65 | 41,700 | 569,205 | 2,664,269 | 2.6 M to 2.7 M (+1.59 %) |
| Jan 12 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 12.83 | 170,338 | 2,185,437 | 2,622,569 | 2.5 M to 2.6 M (+6.95 %) |
| Nov 21 2017 | KALA | Kala Pharmaceutica ... | Bazemore Todd | Chief Operating Off ... | Option Exercise | A | 19.60 | 172,000 | 3,371,200 | 172,000 | |
| Oct 02 2017 | KALA | Kala Pharmaceutica ... | KOVEN ANDREW I | Director | Option Exercise | A | 23.08 | 25,920 | 598,234 | 25,920 | |
| Aug 15 2017 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Option Exercise | M | 3.34 | 12,150 | 40,581 | 149,985 | |
| Aug 15 2017 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Option Exercise | M | 2.30 | 44,313 | 101,920 | 18,247 | |
| Aug 15 2017 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Option Exercise | M | 0.68 | 16,168 | 10,994 | 1,880 | |
| Aug 15 2017 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Option Exercise | M | 0.68 | 36,094 | 24,544 | 0 | |
| Aug 15 2017 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Buy | M | 3.34 | 12,150 | 40,581 | 108,725 | 96.6 K to 108.7 K (+12.58 %) |
| Aug 15 2017 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Buy | M | 2.30 | 44,313 | 101,920 | 96,575 | 52.3 K to 96.6 K (+84.79 %) |
| Aug 15 2017 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Buy | M | 0.68 | 16,168 | 10,994 | 52,262 | 36.1 K to 52.3 K (+44.79 %) |
| Aug 15 2017 | KALA | Kala Pharmaceutica ... | Brazzell Romulus K | Chief Medical Offic ... | Buy | M | 0.68 | 36,094 | 24,544 | 36,094 | 0 to 36.1 K |